Cornerstone Therapeutics

Latest Headlines

Latest Headlines

Chiesi values Cornerstone Therapeutics at $255M in buyout deal

Italy's Chiesi Farmaceutici has finally closed on a deal to snap up the remaining 42% of Cornerstone Therapeutics' shares it doesn't already own--but surprised some speculators who had overbid the deal price. Chiesi flagged its interest for the first time back in February and closed at $9.50 a share, under the $9.74 the stock sold for at the end of last week.

FDA spurns new low-sodium drug from Cornerstone

After getting shot down by a panel of outside experts, the biotech reported this morning that the agency had formally rejected its application for the low-sodium therapy, demanding a new set of "clinical and non-clinical information" before it could reconsider an approval.

UPDATED: FDA panel rejects Cornerstone Therapeutics' heart drug

Cornerstone Therapeutics was dealt a setback today, losing an FDA panel vote on whether their new drug for treating low sodium in the blood should be approved. The agency's outside experts voted 5 to 3 against an approval. They also unanimously rejected the use of the drug to treat heart failure patients.

FDA review backs Cornerstone's new heart drug- with a hitch

Near the beginning of the year Cornerstone Therapeutics snapped up Cardiokine and its late-stage heart drug lixivaptan for a mere $1 million down and $147 million in back-ended milestones.

Cornerstone earns $75M licensing pact

Winston-Salem, NC-based Targacept has inked a $75 million licensing pact for Cornerstone Therapeutics' patents and preclinical programs that target nicotinic receptors. But in keeping with the

FDA wants precaution on Singulair, sister meds

FDA wants some allergy and asthma drugs to come with a new warning of potential psychiatric problems. In an announcement Friday, the agency said it had asked drugmakers to add cautionary language to

Chiesi grabs majority stake in Cornerstone

Italy's Chiesi Farmaceutici will buy a 51 percent stake in Cornerstone Therapeutics, a respiratory drug developer, in a deal valued at $70 million. Investors quickly signalled their disapproval of